Monday, April 6, 2026

Policy

No articles for this category on this date.

Market Access

Market Access•Fierce Pharma•Apr 6, 2026

March M&A surge triggers high expectations for 2026

background ▾

• •Seven transactions exceeding $1 billion closed in 12 days in late March 2026, with combined value of $29 billion, indicating sustained M&A momentum post-Q4 2025 surge
• •At Q1 2026 pace (14 deals ≥$500M vs. 32 in all of 2025), annual M&A value could reach $172 billion compared to $111 billion in 2025—a 55% increase
• •Multiple factors driving deal velocity include improved capital availability, warmed IPO markets, higher biotech valuations (XBI up 64% year-over-year), and psychology of lucrative exit multiples; monitor execution and pipeline integration success in 2H 2026

MerckEli LillyBiogenTERN-701SyfovreEmpaveli

→ Read original article

Clinical Trials

No articles for this category on this date.